Simon Dingemans
   GlaxoSmithKline CFO
   United Kingdom
   GSK CFO interviewed on Q1 2012 results
   GlaxoSmithKline CFO Simon Dingemans looks at the pharma group's overall Q1 performance plus the impact of the company's new financial architecture, the balance between dividend and share buyback, the drug development pipeline and the outlook for the rest of the year.
      
		
    
		| 
		 
		[ close ]
		     Legal Disclaimer  
	
	Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation. Any statements, information and opinions contained in this broadcast, 
	in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend 
	projections and any estimated earnings are or may be forward looking statements and as such involve risks and uncertainties. Actual results and developments may differ materially from those expressed 
	or implied by these statements depending on a variety of factors.  
  
	This broadcast is brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or reliability or completeness of any information provided and accepts no liability for any 
	loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.  |